Research programme: protein kinase inhibitors - Oncodesign

Drug Profile

Research programme: protein kinase inhibitors - Oncodesign

Latest Information Update: 27 Aug 2014

Price : $50

At a glance

  • Originator Oncodesign Biotechnology
  • Class Small molecules
  • Mechanism of Action Receptor-interacting protein serine-threonine kinase 2 inhibitors; Salt-inducible kinase-2 inhibitors; Transforming growth factor beta type II receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Arthritis; Crohn's disease; Glioblastoma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 22 Jul 2014 Early research in Ovarian cancer in France (unspecified route)
  • 22 Jul 2014 Early research in Pancreatic cancer in France (unspecified route)
  • 22 Jul 2014 Early research in Glioblastoma in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top